Abnormal uptake of technetium-99m hexakis-2-methoxyisobutylisonitrile in a primary cardiac lymphoma

Abnormally high uptake of technetium-99m hexakis-2-methoxyisobutylisonitrile (99mTc-SESTAMIBI) in the right ventricle and in the septum was observed in a 47-year-old woman initially presenting with dysarthria and left hemiparesis. Endomyocardial biopsy demonstrated a high-grade malignant non-Hodgkin...

Full description

Saved in:
Bibliographic Details
Published in:European Journal of Nuclear Medicine 1992-03, Vol.19 (3), p.222
Main Authors: Medolago, G, Virotta, G, Pitì, A, Tespili, M, D'Adda, F, Rottoli, M R, Comotti, B, Motta, T, Orlandi, C, Bertocchi, C
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Doxorubicin - administration & dosage
Female
Heart Neoplasms - diagnostic imaging
Heart Neoplasms - drug therapy
Heart Neoplasms - radiotherapy
Humans
Lymphoma, Non-Hodgkin - diagnostic imaging
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - radiotherapy
Middle Aged
Organotechnetium Compounds
Prednisone - administration & dosage
Radionuclide Imaging
Remission Induction
Technetium Tc 99m Sestamibi
Vincristine - administration & dosage
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abnormally high uptake of technetium-99m hexakis-2-methoxyisobutylisonitrile (99mTc-SESTAMIBI) in the right ventricle and in the septum was observed in a 47-year-old woman initially presenting with dysarthria and left hemiparesis. Endomyocardial biopsy demonstrated a high-grade malignant non-Hodgkin's lymphoma. Complete remission was achieved by combined cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy and radiotherapy of the heart and mediastinum. The post-remission single photon emission tomography (SPET) 99mTc-SESTAMIBI study showed a homogeneous distribution pattern, in agreement with echocardiography computed tomography and magnetic resonance imaging. Increased uptake of 99mTc-SESTAMIBI, a myocardial perfusion agent, has been observed in some benign and malignant tumours. It may prove to be useful in the diagnosis and follow-up of malignancies.
ISSN:0340-6997
1619-7089
DOI:10.1007/BF00173286